Group 1 - The core viewpoint is that Sabra Healthcare (SBRA) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][8] - The Zacks rating system is beneficial for individual investors as it provides a clearer picture of earnings estimate revisions, which are crucial for short-term stock price movements [2][14] - The Zacks Consensus Estimate for Sabra has increased by 0.7% over the past three months, reflecting analysts' growing optimism about the company's earnings outlook [11][12] Group 2 - Sabra is projected to earn $1.42 per share for the fiscal year ending December 2024, representing a year-over-year increase of 6.8% [15] - The upgrade to Zacks Rank 2 places Sabra in the top 20% of Zacks-covered stocks, suggesting potential for higher stock prices in the near term [17] - The Zacks rating system maintains a balanced approach, with only the top 5% of stocks receiving a 'Strong Buy' rating, ensuring that Sabra's upgrade reflects its strong earnings estimate revision feature [16]

Group 1 - Healthcare REITs are considered attractive investments due to the stability of demand for healthcare services, which ensures steady cash flow from long-term leases with hospitals, senior living facilities, and medical office buildings [1] - The investment philosophy emphasizes buying high-quality stocks and businesses that are led by disciplined capital allocators, generate exceptional returns on capital, and can compound invested capital over long periods [1]

Portfolio Strategy - The >80 population is expected to grow 4% per year through 2040[7] - As of September 30, 2024, the company has 408 investments and 60 relationships[31] - As of September 30, 2024, the average occupancy percentage is 80% for SNF/TC, 90% for Senior Housing - Leased, and 79% for BH/Hosp/Oth[32] - As of September 30, 2024, the weighted average remaining lease term is 7 years[32] - As of September 30, 2024, SNF/TC EBITDARM coverage is 1.94x, Senior Housing - Leased is 1.37x, and BH/Hosp/Oth is 3.68x[30, 32] - As of September 30, 2024, Skilled Nursing/Transitional Care accounts for 52% of asset class concentration[35] Financial Performance & Guidance - The company updates its 2024 earnings guidance for Net Income to $0.48 - $0.49 per diluted common share[12] - The company updates its 2024 earnings guidance for FFO to $1.35 - $1.36 per diluted common share[12] - The company updates its 2024 earnings guidance for Normalized FFO to $1.39 - $1.40 per diluted common share[12] - The company updates its 2024 earnings guidance for AFFO to $1.41 - $1.42 per diluted common share[12] - The company updates its 2024 earnings guidance for Normalized AFFO to $1.43 - $1.44 per diluted common share[12]

Sabra Healthcare (SBRA) reported $178 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 10.1%. EPS of $0.37 for the same period compares to -$0.07 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $177.19 million, representing a surprise of +0.46%. The company delivered an EPS surprise of +2.78%, with the consensus EPS estimate being $0.36.While investors closely watch year-over-year changes in headline numbers -- revenue and earning ...

Sabra Healthcare (SBRA) came out with quarterly funds from operations (FFO) of $0.37 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to FFO of $0.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an FFO surprise of 2.78%. A quarter ago, it was expected that this health care real estate investment trust would post FFO of $0.35 per share when it actually produced FFO of $0.36, delivering a surprise of 2.86%.Over the l ...

If you've been a follower of mine, then you probably know, or have figured out, that I love to see a good turnaround story. One company that I have "Njoyed" watching turn the corner is Altria ( Contributing analyst to the iREIT+Hoya Capital investment group. The Dividend Collectuh is not a registered investment professional nor financial advisor and these articles should not be taken as financial advice. This is for educational purposes only and I encourage everyone to do their own due diligence. I'm a Navy ...

J SABRA Strategic. Disciplined. Opportunistic. Investor Presentation | August 7, 2024 Disclaimers Forward-Looking Statements This presentation contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Any statements that do not relate to historical or current facts or matters are forward-looking statements. These statements may be identified, without limitation, by the use of "expects," "believes," "intends," "should" or comparable terms or the negative thereo ...

Sabra Healthcare (SBRA) came out with quarterly funds from operations (FFO) of $0.36 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to FFO of $0.34 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an FFO surprise of 2.86%. A quarter ago, it was expected that this health care real estate investment trust would post FFO of $0.34 per share when it actually produced FFO of $0.35, delivering a surprise of 2.94%. Over the ...

Group 1 - Analysts project that Sabra Healthcare (SBRA) will announce quarterly earnings of $0.35 per share, reflecting a year-over-year increase of 2.9% [1] - Revenues are expected to reach $171.51 million, which represents a 6.4% increase from the same quarter last year [1] - The consensus EPS estimate for the quarter has been adjusted upward by 0.4% over the past 30 days, indicating a reassessment by covering analysts [2] Group 2 - Key revenue metrics include 'Revenues- Interest and other income' projected at $8.93 million, a change of +5.5% year over year [5] - 'Revenues- Resident fees and services' are estimated at $68.36 million, suggesting a +17% change from the prior-year quarter [5] - 'Revenues- Rental and related revenues' are forecasted to reach $94.90 million, indicating a +0.7% change from the previous year [5] Group 3 - 'Depreciation and amortization' is projected to be $43.71 million, compared to $44.14 million reported in the same quarter last year [6] - Over the past month, Sabra shares have recorded returns of +4.6%, contrasting with the Zacks S&P 500 composite's -6.7% change [6] - Based on its Zacks Rank 2 (Buy), SBRA is expected to outperform the overall market in the upcoming period [6]

Data by YCharts Editor's Note: This article was submitted as part of Seeking Alpha's Best Growth Idea investment competition, which runs through August 9. With cash prizes, this competition -- open to all analysts -- is one you don't want to miss. If you are interested in becoming an analyst and taking part in the competition, click here to find out more and submit your article today! PM Images The current high interest rate environment has placed a lot of downward pressure on several higher-quality busines ...